217 related articles for article (PubMed ID: 15956255)
1. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
Luo Y; Shoemaker AR; Liu X; Woods KW; Thomas SA; de Jong R; Han EK; Li T; Stoll VS; Powlas JA; Oleksijew A; Mitten MJ; Shi Y; Guan R; McGonigal TP; Klinghofer V; Johnson EF; Leverson JD; Bouska JJ; Mamo M; Smith RA; Gramling-Evans EE; Zinker BA; Mika AK; Nguyen PT; Oltersdorf T; Rosenberg SH; Li Q; Giranda VL
Mol Cancer Ther; 2005 Jun; 4(6):977-86. PubMed ID: 15956255
[TBL] [Abstract][Full Text] [Related]
2. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt.
Ko JH; Yeon SW; Ryu JS; Kim TY; Song EH; You HJ; Park RE; Ryu CK
Bioorg Med Chem Lett; 2006 Dec; 16(23):6001-5. PubMed ID: 16990001
[TBL] [Abstract][Full Text] [Related]
4. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
[TBL] [Abstract][Full Text] [Related]
6. Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling.
Thimmaiah KN; Easton JB; Germain GS; Morton CL; Kamath S; Buolamwini JK; Houghton PJ
J Biol Chem; 2005 Sep; 280(36):31924-35. PubMed ID: 16009706
[TBL] [Abstract][Full Text] [Related]
7. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
[TBL] [Abstract][Full Text] [Related]
8. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.
Zhu GD; Gandhi VB; Gong J; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Jarvis K; Park C; Jong RD; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Jul; 16(13):3424-9. PubMed ID: 16644221
[TBL] [Abstract][Full Text] [Related]
9. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
Feldman RI; Wu JM; Polokoff MA; Kochanny MJ; Dinter H; Zhu D; Biroc SL; Alicke B; Bryant J; Yuan S; Buckman BO; Lentz D; Ferrer M; Whitlow M; Adler M; Finster S; Chang Z; Arnaiz DO
J Biol Chem; 2005 May; 280(20):19867-74. PubMed ID: 15772071
[TBL] [Abstract][Full Text] [Related]
10. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
11. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.
Lin H; Yamashita DS; Zeng J; Xie R; Verma S; Luengo JI; Rhodes N; Zhang S; Robell KA; Choudhry AE; Lai Z; Kumar R; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):679-83. PubMed ID: 20005102
[TBL] [Abstract][Full Text] [Related]
12. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
Cherrin C; Haskell K; Howell B; Jones R; Leander K; Robinson R; Watkins A; Bilodeau M; Hoffman J; Sanderson P; Hartman G; Mahan E; Prueksaritanont T; Jiang G; She QB; Rosen N; Sepp-Lorenzino L; Defeo-Jones D; Huber HE
Cancer Biol Ther; 2010 Apr; 9(7):493-503. PubMed ID: 20139722
[TBL] [Abstract][Full Text] [Related]
13. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of indazole based analog sensitive Akt inhibitors.
Okuzumi T; Ducker GS; Zhang C; Aizenstein B; Hoffman R; Shokat KM
Mol Biosyst; 2010 Aug; 6(8):1389-402. PubMed ID: 20582381
[TBL] [Abstract][Full Text] [Related]
15. Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
Kendall JD; Giddens AC; Tsang KY; Frédérick R; Marshall ES; Singh R; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):58-68. PubMed ID: 22177407
[TBL] [Abstract][Full Text] [Related]
16. Virtual docking approaches to protein kinase B inhibition.
Forino M; Jung D; Easton JB; Houghton PJ; Pellecchia M
J Med Chem; 2005 Apr; 48(7):2278-81. PubMed ID: 15801821
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.
DeFeo-Jones D; Barnett SF; Fu S; Hancock PJ; Haskell KM; Leander KR; McAvoy E; Robinson RG; Duggan ME; Lindsley CW; Zhao Z; Huber HE; Jones RE
Mol Cancer Ther; 2005 Feb; 4(2):271-9. PubMed ID: 15713898
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
[TBL] [Abstract][Full Text] [Related]
20. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer.
Li Q; Zhu GD
Curr Top Med Chem; 2002 Sep; 2(9):939-71. PubMed ID: 12171565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
